医学
杀精剂
怀孕
临床试验
阴道环
激素避孕
柠檬酸
衣原体
药理学
随机对照试验
药方
妇科
产科
内科学
计划生育
人口
免疫学
化学
环境卫生
有机化学
生物
研究方法
遗传学
作者
Shanna Su,Kathleen L. Vincent
标识
DOI:10.1080/17512433.2022.2100347
摘要
Introduction A non-hormonal prescription vaginal pH modulator (VPM) gel (Phexxi®), with active ingredients lactic acid, citric acid and potassium bitartrate, has recently been approved for prevention of pregnancy in the United States. The objective of this review is to compile the evidence available from published preclinical and clinical trials to support its use.Areas covered PubMed was searched for published literature on VPM gel. Two Phase III trials were found on clinicaltrials.gov database. The results demonstrated that VPM gel is safe, with minimal side effects, and effective (cumulative 6–7 cycle pregnancy rate of 4.1–13.65%, (Pearl Index 27.5) as a contraceptive. Microbicidal effects suggest potential for the prevention of sexually transmitted infections (STIs); currently a Phase III clinical trial is being conducted to evaluate prevention of chlamydia and gonorrhea.Expert opinion Non-hormonal reversible contraceptive options have been limited to the highly effective copper-releasing intrauterine device that requires insertion by a trained clinician, and less effective coitally associated barrier and spermicide options which are typically available over-the-counter. Spermicides, which improve efficacy of barrier devices, may increase the risk of HIV/STIs. VPM gel provides a new safe, effective non-hormonal contraceptive option, with potential for prevention of STIs.
科研通智能强力驱动
Strongly Powered by AbleSci AI